Shimano K, Kondo O, Miwa A, Higashi Y, Koyama I, Yoshida T, Ito Y, Hirose J, Goto S
Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, 330, Japan.
Kobe Steel, Ltd., 1-3-18, Wakinohama-cho, Chuo-ku, Kobe, 651, Japan.
Drug Dev Ind Pharm. 1995;21(3):331-347. doi: 10.3109/03639049509048114.
In order to prepare microcapsules (MC) using polyvinylacetal diethyl-aminoacetate (AEA) gel, we have studied both the unique properties of AEA gel, in which cold-water solution forms a hard gel with exclusion of water at high temperature, and the microencapsulation technique for clarithromycin (CAM), which has an unpleasant taste (1, 2). In our previous paper (3), we described a new uniform-sized microencapsulation machine with a vibration nozzle with 536 holes 100µ in diameter designed for precise regulation of dissolution of CAM from MC.In order to evaluate the MC thus obtained, we prepared syrups (without water) by adding sweetening agents to MC, and conducted a dissolution test at various pHs using the method described in the Japanese Pharmacopoeia (12th edition), a test for bitter taste and a test to determine bioavailability (BA) in human subjects. At pHs below 4.0,100% of CAM in MC was dissolved from the syrup within 5min. However, there was little dissolution of CAM from syrup at pH6.8. The results of the test for bitter taste showed that the syrup preparations, which were administered to 12 male and female volunteers with 20ml water, masked bitter taste completely during the 60min period following administration of the syrup. The mean area under the serum concentration-time curve (AUCo-24) and the maximum serum concentration (Cmax) for administration of syrup preparations to 6 male volunteers were 5.66 ± 0.73µg·hr/ml and 0.66 ± 0.13µg/ml, respectively. Blood concentration was maintained at a level above the minimum inhibitory concentration for gram-positive bacteria for a period of about 14hr after administration, demonstrating the usefulness of the syrup preparation.
为了使用聚乙烯醇缩乙醛二乙胺基乙酸酯(AEA)凝胶制备微胶囊(MC),我们研究了AEA凝胶的独特性质(其冷水溶液在高温下会形成硬凝胶并排除水分)以及克拉霉素(CAM)的微囊化技术(CAM有令人不悦的味道)(1, 2)。在我们之前的论文(3)中,我们描述了一种新型的尺寸均匀的微囊化机器,它带有一个有536个直径为100µ的孔的振动喷嘴,用于精确调节CAM从MC中的溶出。为了评估由此获得的MC,我们通过向MC中添加甜味剂制备了糖浆(无水),并使用日本药典(第12版)中描述的方法在不同pH值下进行了溶出试验、苦味测试以及在人体受试者中测定生物利用度(BA)的测试。在pH值低于4.0时,MC中的CAM在5分钟内从糖浆中100%溶出。然而,在pH6.8时,CAM从糖浆中的溶出很少。苦味测试结果表明,给12名男性和女性志愿者服用20ml水的糖浆制剂,在服用糖浆后的60分钟内完全掩盖了苦味。给6名男性志愿者服用糖浆制剂后的血清浓度 - 时间曲线下的平均面积(AUCo - 24)和最大血清浓度(Cmax)分别为5.66±0.73µg·hr/ml和0.66±0.13µg/ml。给药后,血液浓度在约14小时内维持在高于革兰氏阳性菌最低抑菌浓度的水平,证明了糖浆制剂的有效性。